Evidence map›Paper›PMID 32883230›Full record

ArticleBMC cancer2020

Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.

Dan Zhang, Xiuying Chen, Hexia Xia, Lu Wang, Hongbo Zhao, Bufang Xu, Aijun Zhang, Wei Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dan ZhangObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China.
Xiuying ChenObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China.
Hexia XiaObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China.
Lu WangObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China.
Hongbo ZhaoObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China.
Bufang XuReproductive Medical Center of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197 Ruijin Second Road, Shanghai, 200025, China.
Aijun ZhangReproductive Medical Center of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, 197 Ruijin Second Road, Shanghai, 200025, China.
Wei ZhangObstetrics and Gynecology Hospital, Fudan University, Postal address: 413 Zhaozhou Road, Shanghai, 200011, China. zhangwei623@hotmail.com.ORCID http://orcid.org/0000-0001-7187-108X
Obstetrics and Gynecology Hospital of Fudan University · CNShanghai Jiao Tong University · CN

Funding

Merck-Serono Chinese Research Fund MerckSerono_CREATE-2016116National Natural Science Foundation of China 81701513National Natural Science Foundation of China 8177060587Specialized Research Fund for New Teachers of Chinese Higher Education Doctoral Program 20130071120095
6 · The paper itself

Abstract

backgroundEndometrial cancer, one of the most common malignant tumors, is a serious threat to women's health. Endometrial hyperplasia is a precursor of endometrial cancer. S100 calcium binding protein P (S100P) has been found to play important roles in many types of cancer. The present study aimed to investigate the expression of S100P in endometrial cancer and its precursor lesions, and to explore the possible mechanisms.

methodsWe collected paraffin sections of normal endometrium, simple and complex non-atypical hyperplasia, atypical hyperplasia, and endometrioid carcinoma. The expression of S100P in endometrial cancer and its precancerous lesions was observed using immunohistochemistry. We also cultured primary endometrial cells and endometrial cancer cell lines (Ishikawa and RL95-2), and observed the expression of S100P in these cells. Laser confocal microscopy was used to observe the co-localization of S100P and its interacting protein Ezrin in RL95-2 cells. We employed lentiviruses to knockdown and overexpress S100P and then detected the F-actin distribution and cell invasion using phalloidin staining and Transwell assays.

resultsThere was a gradual increase in the S100P signal as the disease progressed from normal endometrium and simple non-atypical hyperplasia, to complex non-atypical hyperplasia, atypical hyperplasia, and then to endometrial cancer. S100P was mainly distributed in the cytoplasm and co-localized with Ezrin in endometrial cancer cells. After knocking down S100P, F-actin aggregated in the nucleus or to the local cell membrane. Furthermore, knockdown of S100P in Ishikawa cells decreased their cell invasion capability. Meanwhile, S100P overexpression in endometrial stromal cells increased cell invasion.

conclusionsThese data suggested that S100P might be involved in the occurrence and development of endometrial cancer via interaction with Ezrin and re-organization of F-actin to promote cell invasion.

Indexed as

Disease ProgressionActinsAdultCalcium-Binding ProteinsCarcinoma, EndometrioidCell Line, TumorCytoskeletal ProteinsEndometrial NeoplasmsEzrinFemaleGene Knockdown TechniquesHumansImmunohistochemistryNeoplasm InvasivenessNeoplasm ProteinsPrecancerous ConditionsActinsCalcium-Binding ProteinsCytoskeletal ProteinsEzrinNeoplasm ProteinsS100P protein, humanCell invasionCytoskeletal rearrangementEndometrial cancerEzrinS100 calcium binding protein P

Identifiers

PMID32883230
PMCPMC7650527
OpenAlexW3083420827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.